The FDA has given a thumbs up to a treatment for acute radiation exposure developed by Pluristem Therapeutics.
The company, which develops placenta-based stem cell therapies, said the drug, PLX-R18, was approved for emergency use following a nuclear event. Pending positive results from another phase 3 clinical trial, Pluristem hopes it will gain approval for a wider range of situations, including bone marrow failure from other causes.
The company said the cells can be used without tissue matching and that one placenta can produce about 20,000 treatments.
Several government agencies have supported studies for PLX-R18, including the U.S. Department of Defense.
Read the full Reuters report.